Research analysts covering MIRA PHARMACEUTICALS.
Recent press releases and 8-K filings for MIRA.
MIRA Pharmaceuticals Announces Positive Preclinical Data for Mira-55
MIRA
Product Launch
New Projects/Investments
- On October 15, 2025, MIRA Pharmaceuticals, Inc. announced new preclinical data for its proprietary non-psychotropic marijuana analog, Mira-55.
- The study demonstrated that oral administration of Mira-55 normalized pain and significantly reduced inflammation, outperforming injected morphine in an established animal model of chronic inflammatory pain.
- This marks the first time inflammation was directly measured in the Mira-55 program, showing superior pain normalization and direct anti-inflammatory effects compared to morphine's partial and indirect reduction.
- These findings support MIRA's plan to pursue an Investigational New Drug (IND) application for chronic inflammatory pain, reinforcing its position in the $70 billion non-opioid pain market.
Oct 15, 2025, 8:01 PM
MIRA Pharmaceuticals Completes Acquisition of SKNY Pharmaceuticals
MIRA
M&A
New Projects/Investments
Delisting/Listing Issues
- MIRA Pharmaceuticals, Inc. completed the acquisition of SKNY Pharmaceuticals, Inc. on September 29, 2025, acquiring 100% of SKNY in exchange for restricted shares of MIRA's common stock.
- As a condition to closing, SKNY contributed $5 million in marketable securities to MIRA, strengthening the Company’s balance sheet.
- The acquisition expands MIRA's pipeline, positioning it as a multi-program biopharmaceutical developer with programs addressing high-value therapeutic areas, including Ketamir-2 (Phase 1 for neuropathic pain), MIRA-55 (oral THC analog for inflammatory pain), and SKNY-1 (oral therapeutic for obesity and smoking cessation).
- MIRA believes it has regained compliance with Nasdaq's minimum $2,500,000 stockholders' equity rule as of the date of the report, following the acquisition and other stock sales.
Sep 30, 2025, 11:00 AM
MIRA Pharmaceuticals Reports Positive PTSD Data for Ketamir-2
MIRA
New Projects/Investments
- MIRA Pharmaceuticals, Inc. announced positive results from a proof-of-concept validation study for its oral drug candidate, Ketamir-2, in an animal model of post-traumatic stress disorder (PTSD) on September 15, 2025.
- The study demonstrated that Ketamir-2 treatment was associated with a reversal of PTSD-like behaviors (such as increased despair and immobility) in stressed animals, returning them to levels observed in non-stressed animals.
- Ketamir-2 is a proprietary, orally bioavailable new molecular entity designed to provide the therapeutic efficacy of ketamine while minimizing dissociative and central nervous system side effects, and it has been determined not to be a controlled substance by the U.S. Drug Enforcement Administration.
- A larger follow-on PTSD study is currently ongoing, and Ketamir-2 is also being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, where it has shown a favorable safety profile to date.
Sep 15, 2025, 8:02 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more